Semi-annual Report in 2024
Filed with SSE · · 199 pages · Chinese
Earlier from InnoCare Pharma
- Announcement on Convening the 2024 Semi-Annual Performance Briefing
- Announcement on Voluntary Disclosure of Completing the 1st Administration of ICP-332 in Patients in the United States
- Indicative Announcement on Change in Equity of Shareholder with Over 5% Shares
- Announcement on the "Corporate Value and Return Enhancement" Action Plan 2024
Later from InnoCare Pharma
- Announcement on Voluntary Disclosure of Clinical Trial Progress of Aobrutinib
- Announcement on Listing and Circulation of Initial Public Offering of Strategic Placement Restricted Shares
- Announcement on Change of Sponsor Representative for Continuous Supervision
- Announcement on the Resignation of Non-executive Directors and Independent Non-executive Directors and the Change of Members of Special Committees of the Board of Directors
- Announcement on Voluntary Disclosure of Phase II Clinical Trial Result of ICP-488
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma